Short answer
Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Chief Commercial Officer Nicholas Grund resigns for personal reasons, effective November 6, 2026.
Akebia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Commercial Officer Nicholas Grund resigns for personal reasons, effective November 6, 2026
- Consulting arrangement continues through April 30, 2027, supporting commercial transition
- Hourly consulting compensation and termination notice provisions govern the interim advisory period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Akebia Therapeutics, Inc. 8-K filings
Get the next AKBA 8-K as it lands
Follow AKBA for push alerts, or ask the research agent what this filing means.